News Quantified

BIIB – biogen inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Biogen Inc. (NASDAQ: BIIB) had its price target raised by analysts at HSBC Holdings plc from $339.00 to $342.00. They now have a "buy" rating on the stock.

Biogen Reports Progress on Corporate Responsibility Priorities [Yahoo! Finance]

Biogen Reports Progress on Corporate Responsibility Priorities

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]

Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings [Seeking Alpha]

3.2%

BEAT

0.2%

BEAT

-1.9%

BEAT

1.2%

MISS

Oppenheimer Holdings Inc.

Form 4 BIOGEN INC. For: May 01 Filed by: Keeney Adam

Form ARS BIOGEN INC. For: Dec 31

Form DEFA14A BIOGEN INC.

Form DEF 14A BIOGEN INC. For: Jun 20

Form 10-Q BIOGEN INC. For: Mar 31

Top News Gainers

10/22 Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies 25.3%

2/5 Form SC 13G/A BIOGEN INC. Filed by: BlackRock Inc. 17.6%

3/12 Form 4 BIOGEN INC. For: Mar 11 Filed by: SHERWIN STEPHEN A 15.1%

3/16 Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World 8.4%

3/2 Biogen Inc (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. 6.2%

7/23 Biogen profit rises 72% on multiple sclerosis therapy sales [Reuters] 4.7%

4/2 Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study 4.3%

3/3 Why Biogen Stock Rose 14.7% in February [The Motley Fool] 4.0%

2/3 Form 8-K BIOGEN INC. For: Jan 28 3.9%

11/22 Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) 3.7%

Top News Decliners

10/22 Biogen's stock rockets after earnings beat, Alzheimer's treatment heads for regulatory approval process [MarketWatch] -11.9%

2/5 U.S. patent office rules in favor of Biogen over Mylan for MS drug [Reuters] -9.1%

3/7 Is Biogen Inc. (BIIB) A Good Stock To Buy? [Yahoo! Finance News] -5.7%

4/22 Q1/2020 3/31/2020 EPS 9.140 ZacksConsensus 7.740 ActVsEst 1.400 - Beat -5.1%

2/27 Biogen Inc (NASDAQ: BIIB) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -4.9%

3/18 Coronavirus delays Biogen's Spinraza for some patients [Reuters (UK)] -4.5%

1/30 Biogen beats profit estimates on demand for multiple sclerosis drug [Reuters] -4.0%

10/23 Biogen Inc (NASDAQ: BIIB) had its price target raised by analysts at Morgan Stanley from $212.00 to $262.00. They now have an "underweight" rating on the stock. -3.5%

1/30 Biogen Inc (NASDAQ: BIIB) had its "neutral" rating re-affirmed by analysts at Wedbush. -3.2%

10/2 Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders -3.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day